EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2a

Ensembl ID : ENSMAMG00000008597
Gene Symbol: GABRB2A
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSMAMG00000005647
Gene Symbol: GABRB3
3 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSMAMG00000010538
Gene Symbol: GABRB3
1 Cross references
187 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSMAMG00000014755
Gene Symbol: GABRD
2 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSMAMG00000016472
Gene Symbol: GABRG1
2 Cross references
187 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSMAMG00000021473
Gene Symbol: GABRG2
3 Cross references
206 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSMAMG00000011836
Gene Symbol: GABRG3
3 Cross references
215 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSMAMG00000005586
Gene Symbol: GABRG3
3 Cross references
214 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSMAMG00000015307
Gene Symbol: GIPR
2 Cross references
185 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSMAMG00000019992
Gene Symbol: GLP2R
2 Cross references
204 Possible Orthologues:

Glucokinase (Hexokinase 4)

Ensembl ID : ENSMAMG00000013140
Gene Symbol: GCK
2 Cross references
211 Possible Orthologues:

Glucosidase, Alpha; Acid (Pompe Disease, Glycogen Storage Disease Type Ii)

Ensembl ID : ENSMAMG00000023442
Gene Symbol: GAA
2 Cross references
234 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).